Apogee Therapeutics, Inc. (APGE)

135.08 0.00 (0.00%) USD  |  NASDAQ  |  Sep 01, 14:04
More

Apogee Therapeutics Total Long Term Debt (Quarterly) : 103.70M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for APGE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2022. Start Trial.
Date Value
June 30, 2026 103.70M
March 31, 2026 4.909M
December 31, 2025 5.345M
September 30, 2025 5.774M
June 30, 2025 6.82M
March 31, 2025 7.84M
December 31, 2024 8.597M
September 30, 2024 9.273M
June 30, 2024 2.401M
Date Value
March 31, 2024 0.63M
December 31, 2023 0.933M
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Cogent Biosciences, Inc. 242.77M
Arrowhead Pharmaceuticals, Inc. 1.371B
Intellia Therapeutics, Inc. 50.07M
Revolution Medicines, Inc. 1.174B
Erasca, Inc. 39.27M